MicroCarb Inc. and Pasteur Merieux Serums and Vaccins areexpected to begin clinical trials this year with MicroCarb's otitismedia vaccine for nontypable Haemophilus influenzae, which causesear infections.
Vic Esposito, MicroCarb's chairman and CEO, said hisGaithersburg, Md.-based company has entered into a collaborationwith Pasteur Merieux, of Lyon, France, to develop the vaccine,which showed success in combating the infection in animal models.
Esposito said the agreement with Pasteur Merieux, a subsidiary ofFrance-based Rhone-Poulenc Group, represents the first licensingdeal for MicroCarb's adhesin-receptor technology.
Financial details of the collaboration were not disclosed. Espositosaid MicroCarb granted Pasteur Merieux worldwide marketingrights, except in countries of the Pacific Basin. In return, MicroCarbwill receive license fees, milestone payments and royalties.
Esposito said Pasteur Merieux and its affiliate, ConnaughtLaboratories, of Toronto, will conduct the clinical trials, which areexpected to begin this year. _ Charles Craig
(c) 1997 American Health Consultants. All rights reserved.